Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/1/2021 | $16.00 | Buy | Roth Capital |
| 10/6/2021 | $15.00 | Buy | Maxim Group |
4 - RenovoRx, Inc. (0001574094) (Issuer)
3/A - RenovoRx, Inc. (0001574094) (Issuer)
4 - RenovoRx, Inc. (0001574094) (Issuer)
MOUNTAIN VIEW, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that it has been named on Fast Company's prestigious list of the World's Most Innovative Companies of 2026 as number 10 in the medical device category. This annual recognition highlights organizations that are shaping industry and culture through their innovations. "We're honored to be named one of the 2026 World's Most Innovative Medical Device Companies by Fast Company," said Shaun Bagai, Chief Executive
RenovoCath® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data Anticipated in 2027 With $13 Million on Hand, Company has the Funding, Business Plan, Leadership, and Infrastructure to Drive Growth and Shareholder Value Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced its f
TIGeR-PaC Trial Enrollment Remains on Track for Completion in First Half of 2026, with Final Data Expected in 2027 Select TIGeR-PaC Cancer Centers Now Using RenovoCath® as a Stand-Alone Device for Drug-Delivery in Oncology Management MOUNTAIN VIEW, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced the Company has achieved a key milestone in its ongoing Phase III TIGeR‑PaC clinical trial by surpassing 100 randomized patients and remains on track for enrollment completion
Roth Capital initiated coverage of RenovoRx with a rating of Buy and set a new price target of $16.00
Maxim Group initiated coverage of RenovoRx with a rating of Buy and set a new price target of $15.00
4 - RenovoRx, Inc. (0001574094) (Issuer)
4 - RenovoRx, Inc. (0001574094) (Issuer)
4 - RenovoRx, Inc. (0001574094) (Issuer)
S-8 - RenovoRx, Inc. (0001574094) (Filer)
8-K - RenovoRx, Inc. (0001574094) (Filer)
10-K - RenovoRx, Inc. (0001574094) (Filer)
Over the past year, RenovoRx has Tripled Commercially Active U.S. Cancer Centers and Centers Requesting Access to RenovoCath, its FDA-Cleared Device Over 700 RenovoCath Procedures Successfully Completed Since FDA Clearance in 2014 Company Appoints Ramtin Agah, MD to the Additional Position of Executive Chairman to Support Continued Clinical Adoption and Commercial Growth MOUNTAIN VIEW, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced continued commercial progress, with
MOUNTAIN VIEW, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, is pleased to announce the appointment of Mark Voll as the Company's Chief Financial Officer, effective February 1, 2026. Mr. Voll brings more than three decades of financial leadership experience to RenovoRx, with a strong track record for guiding high-growth public companies through periods of commercial buildout and strategic development. He has served as Chief Financial Officer for multiple publicly traded technology co
MOUNTAIN VIEW, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced the appointment of renowned UCLA surgeon and pancreatic disease expert Timothy Donahue, MD, to RenovoRx's scientific advisory board (SAB). Dr. Donahue is a nationally recognized expert in pancreatic cancer and serves as the Director of UCLA's Agi Hirshberg Center for Pancreatic Diseases and as Chief of the Division of Surgical Oncology at the David Geffen School of Medicine. He also holds the Garry Shandling Ch
SC 13G/A - RenovoRx, Inc. (0001574094) (Subject)
SC 13G - RenovoRx, Inc. (0001574094) (Subject)
SC 13G - RenovoRx, Inc. (0001574094) (Subject)
RenovoCath® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data Anticipated in 2027 With $13 Million on Hand, Company has the Funding, Business Plan, Leadership, and Infrastructure to Drive Growth and Shareholder Value Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced its f
MOUNTAIN VIEW, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that it will host its fourth quarter and full year 2025 financial results and business highlights conference call on March 30, 2026, at 4:30 p.m. ET. Additional details will be available on the Investor Relations section of the Company's website at https://ir.renovorx.com/. On the call, RenovoRx's management team is expected to discuss the continued progress in RenovoCath adoption among U.S. cancer centers,
September 30, 2025 Cash and Cash Equivalents at $10 million Revenue Expected to Grow in 2026 and Continue to Offset Cash Burn Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (NASDAQ:RNXT) ("RenovoRx" or the "Company"), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced its financial results and provided a business update to shareholders for the third quarter ended September 30, 2025. "We continue to make strong progress both in our commercial and clinical activities," said Shaun Bagai, CEO of